Thezenas S - Search Results

1

Surgical Margins and Adjuvant Therapies in Malignant Phyllodes Tumors of the Breast: A Multicenter Retrospective Study.

Neron M, Sajous C, Thezenas S, Piperno-Neumann S, Reyal F, Laé M, Chakiba C, Michot A, Penel N, Honoré C, Owen C, Bertucci F, Salas S, Saada-Bouzid E, Valentin T, Bompas E, Brahmi M, Ray-Coquard I, Blay JY, Firmin N; French Sarcoma Group (GSF-GETO). Neron M, et al. Among authors: thezenas s. Ann Surg Oncol. 2020 Jun;27(6):1818-1827. doi: 10.1245/s10434-020-08217-y. Epub 2020 Jan 27. Ann Surg Oncol. 2020. PMID: 31989361

2

A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial.

Ychou M, Rivoire M, Thezenas S, Quenet F, Delpero JR, Rebischung C, Letoublon C, Guimbaud R, Francois E, Ducreux M, Desseigne F, Fabre JM, Assenat E. Ychou M, et al. Among authors: thezenas s. Ann Surg Oncol. 2013 Dec;20(13):4289-97. doi: 10.1245/s10434-013-3217-x. Epub 2013 Aug 17. Ann Surg Oncol. 2013. PMID: 23955585 Clinical Trial.

3

Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision-making for early breast cancer.

Saadoun H, Lamy PJ, Thezenas S, Pouderoux S, Bibeau F, Montels F, Romieu G, Colombo PE, Gutowski M, Jacot W. Saadoun H, et al. Among authors: thezenas s. Future Oncol. 2014 Feb;10(2):195-209. doi: 10.2217/fon.13.177. Future Oncol. 2014. PMID: 24490606

4

Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases.

Jacot W, Pons E, Frenel JS, Guiu S, Levy C, Heudel PE, Bachelot T, D'Hondt V, Darlix A, Firmin N, Romieu G, Thezenas S, Dalenc F. Jacot W, et al. Among authors: thezenas s. Breast Cancer Res Treat. 2016 Jun;157(2):307-318. doi: 10.1007/s10549-016-3828-6. Epub 2016 May 11. Breast Cancer Res Treat. 2016. PMID: 27167986

5

Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients.

Darlix A, Lamy PJ, Lopez-Crapez E, Braccini AL, Firmin N, Romieu G, Thezenas S, Jacot W. Darlix A, et al. Among authors: thezenas s. BMC Cancer. 2016 Jul 7;16:428. doi: 10.1186/s12885-016-2448-1. BMC Cancer. 2016. PMID: 27387327 Free PMC article.

6

Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases?

Darlix A, Lamy PJ, Lopez-Crapez E, Braccini AL, Firmin N, Romieu G, Thézenas S, Jacot W. Darlix A, et al. Among authors: thezenas s. Int J Cancer. 2016 Nov 15;139(10):2299-311. doi: 10.1002/ijc.30290. Epub 2016 Aug 6. Int J Cancer. 2016. PMID: 27464303

7

Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer.

Darlix A, Griguolo G, Thezenas S, Kantelhardt E, Thomssen C, Dieci MV, Miglietta F, Conte P, Braccini AL, Ferrero JM, Bailleux C, Jacot W, Guarneri V. Darlix A, et al. Among authors: thezenas s. J Neurooncol. 2018 Jun;138(2):369-382. doi: 10.1007/s11060-018-2805-9. Epub 2018 Feb 27. J Neurooncol. 2018. PMID: 29488184

8

Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective study.

Viala M, Chiba A, Thezenas S, Delmond L, Lamy PJ, Mott SL, Schroeder MC, Thomas A, Jacot W. Viala M, et al. Among authors: thezenas s. BMC Cancer. 2018 Jul 30;18(1):770. doi: 10.1186/s12885-018-4686-x. BMC Cancer. 2018. PMID: 30060745 Free PMC article.

9

The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases.

Darlix A, Hirtz C, Thezenas S, Maceski A, Gabelle A, Lopez-Crapez E, De Forges H, Firmin N, Guiu S, Jacot W, Lehmann S. Darlix A, et al. Among authors: thezenas s. BMC Cancer. 2019 Jan 30;19(1):110. doi: 10.1186/s12885-019-5287-z. BMC Cancer. 2019. PMID: 30700265 Free PMC article.

10

Impact of Metastasis Surgery and Alkylating-Agent-Based Chemotherapy on Outcomes of Metastatic Malignant Phyllodes Tumors: A Multicenter Retrospective Study.

Neron M, Sajous C, Thezenas S, Piperno-Neumann S, Reyal F, Laé M, Chakiba C, Penel N, Ryckewaert T, Honoré C, Bertucci F, Monneur A, Salas S, Duffaud F, Saada-Bouzid E, Isambert N, Brahmi M, Ray-Coquard I, Blay JY, Firmin N; French Sarcoma Group (GSF-GETO). Neron M, et al. Among authors: thezenas s. Ann Surg Oncol. 2020 May;27(5):1693-1699. doi: 10.1245/s10434-019-08097-x. Epub 2019 Nov 26. Ann Surg Oncol. 2020. PMID: 31773519

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

91 results

Search Page

Filters